These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 3934126)
1. A prospective study of adverse reactions associated with vancomycin therapy. Sorrell TC; Collignon PJ J Antimicrob Chemother; 1985 Aug; 16(2):235-41. PubMed ID: 3934126 [TBL] [Abstract][Full Text] [Related]
2. Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice. Elting LS; Rubenstein EB; Kurtin D; Rolston KV; Fangtang J; Martin CG; Raad II; Whimbey EE; Manzullo E; Bodey GP Cancer; 1998 Dec; 83(12):2597-607. PubMed ID: 9874468 [TBL] [Abstract][Full Text] [Related]
3. Chromatographically purified vancomycin: therapy of serious infections caused by Staphylococcus aureus and other gram-positive bacteria. Wang LS; Liu CY; Wang FD; Fung CP; Chiu ZH; Cheng DL Clin Ther; 1988; 10(5):574-84. PubMed ID: 2856600 [TBL] [Abstract][Full Text] [Related]
4. Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. Goetz MB; Sayers J J Antimicrob Chemother; 1993 Aug; 32(2):325-34. PubMed ID: 8226435 [TBL] [Abstract][Full Text] [Related]
5. Comparison of pharmacokinetics and bactericidal activity of teicoplanin and vancomycin. Lagast H; Dodion P; Klastersky J J Antimicrob Chemother; 1986 Oct; 18(4):513-20. PubMed ID: 2945811 [TBL] [Abstract][Full Text] [Related]
6. Vancomycin ototoxicity: a reevaluation in an era of increasing doses. Forouzesh A; Moise PA; Sakoulas G Antimicrob Agents Chemother; 2009 Feb; 53(2):483-6. PubMed ID: 19001107 [TBL] [Abstract][Full Text] [Related]
7. Frequencies of subpopulations of aminoglycoside- and vancomycin-resistant variants in Staphylococcus aureus and Staphylococcus epidermidis. Rådberg G; Nilsson LE; Kihlström E; Maller R; Sörén L J Antimicrob Chemother; 1992 Oct; 30(4):489-96. PubMed ID: 1490921 [TBL] [Abstract][Full Text] [Related]
8. Effects of demethylfruticuline A and fruticuline A from Salvia corrugata Vahl. on biofilm production in vitro by multiresistant strains of Staphylococcus aureus, Staphylococcus epidermidis and Enterococcus faecalis. Schito AM; Piatti G; Stauder M; Bisio A; Giacomelli E; Romussi G; Pruzzo C Int J Antimicrob Agents; 2011 Feb; 37(2):129-34. PubMed ID: 21163629 [TBL] [Abstract][Full Text] [Related]
10. Lack of nephrotoxicity in pediatric patients receiving concurrent vancomycin and aminoglycoside therapy. Nahata MC Chemotherapy; 1987; 33(4):302-4. PubMed ID: 3608631 [TBL] [Abstract][Full Text] [Related]
11. A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection. Schrenzel J; Harbarth S; Schockmel G; Genné D; Bregenzer T; Flueckiger U; Petignat C; Jacobs F; Francioli P; Zimmerli W; Lew DP; Clin Infect Dis; 2004 Nov; 39(9):1285-92. PubMed ID: 15494904 [TBL] [Abstract][Full Text] [Related]
12. In-vitro comparison of the post-antibiotic effect of vancomycin and teicoplanin. Cooper MA; Jin YF; Ashby JP; Andrews JM; Wise R J Antimicrob Chemother; 1990 Aug; 26(2):203-7. PubMed ID: 2145256 [TBL] [Abstract][Full Text] [Related]
13. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. Noble WC; Virani Z; Cree RG FEMS Microbiol Lett; 1992 Jun; 72(2):195-8. PubMed ID: 1505742 [TBL] [Abstract][Full Text] [Related]
17. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269 [TBL] [Abstract][Full Text] [Related]
18. Epidemiologic characteristics of resistant microorganisms present in reserves from an intensive care unit. de Oliveira AC; Damasceno QS; Piscoya M; Nicoli JR Am J Infect Control; 2012 Mar; 40(2):186-7. PubMed ID: 21824685 [TBL] [Abstract][Full Text] [Related]
19. [Recent findings based on the results of the post-marketing surveillance of vancomycin hydrochloride for intravenous infusion]. Shimada K Jpn J Antibiot; 2003 Aug; 56(4):259-71. PubMed ID: 14567250 [TBL] [Abstract][Full Text] [Related]
20. [Clinical studies on vancomycin in the treatment of MRSA infection]. Shimizu K; Orizu M; Kanno H; Kitamura S; Konishi T; Soma K; Nishitani H; Noguchi Y; Hasegawa S; Hasegawa H; Wada K Jpn J Antibiot; 1996 Aug; 49(8):782-99. PubMed ID: 9053533 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]